Generic Lenacapavir HIV Prevention Shot Expected on Market by End-2026
ESTIMATEDDate confidence: ESTIMATEDA target, not a fixed dateHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all ESTIMATED pins70% CONFIDENCEOverall confidence: 70%How well the pin's source and references back up its dates.Weighted average of how firmly 5 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins from 50% to 74% confidencein 90 daysThe Global Fund[1][3] writes "Generic lenacapavir is expected to enter the market by the end of 2026", giving no day, so the pin takes 31 December.
The Global Fund expects generic lenacapavir, the twice-yearly HIV prevention injection, to enter the market by the end of 2026, with 24 countries worldwide due to receive it by then. Nearly 100,000 people in nine high-burden African countries had received it by mid-August 2026.
Wilmar International